Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride

E. Stoner, E. Round, D. Ferguson, G. J. Gormley, G. L. Andriole, R. Boake, M. Elhilali, J. P. Perreault, J. Trachtenburg, R. Norman, R. Rittmaster, B. R. Braken, M. I. Resnick, W. Brannan, H. Fuselier, R. C. Bruskewitz, G. H. Malek, C. E. Cox, Anthony Patterson

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The clinical experience relating to the detection of prostate cancer in patients participating in 2 large multicenter clinical trials of finasteride in the treatment of benign prostatic hyperplasia is reviewed. A total of 1,645 patients 40 to 83 years old with benign prostatic hyperplasia was randomized to receive 1 or 5 mg. finasteride or placebo once a day for 12 months in a double-blind fashion followed by an open extension study in which all patients were treated with 5 mg. finasteride daily. At entry, all patients were to have a maximum urinary flow rate of 15 ml. per second or less with a voided volume of 150 ml. or more, an enlarged prostate and symptoms of urinary obstruction. Patients with a prostate specific antigen level of 40 ng./ml. or more, or any finding suggestive of prostate cancer were excluded. During the study period 32 cases of prostate cancer were diagnosed: 12 were detected during the 12 months of the controlled study and were evenly distributed among the treatment groups (4 on placebo, and 3 on 1 mg. and 5 on 5 mg. finasteride) and 20 cases were detected in the extension study. From these results we conclude that finasteride-treated patients should be evaluated periodically by digital rectal examination, careful monitoring of prostate specific antigen levels and appropriate investigation of any suspicious findings.

Original languageEnglish (US)
Pages (from-to)1296-1300
Number of pages5
JournalJournal of Urology
Volume151
Issue number5
DOIs
StatePublished - Jan 1 1994

Fingerprint

Finasteride
Prostatic Hyperplasia
Prostatic Neoplasms
Prostate-Specific Antigen
Placebos
Digital Rectal Examination
Multicenter Studies
Prostate
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride. / Stoner, E.; Round, E.; Ferguson, D.; Gormley, G. J.; Andriole, G. L.; Boake, R.; Elhilali, M.; Perreault, J. P.; Trachtenburg, J.; Norman, R.; Rittmaster, R.; Braken, B. R.; Resnick, M. I.; Brannan, W.; Fuselier, H.; Bruskewitz, R. C.; Malek, G. H.; Cox, C. E.; Patterson, Anthony.

In: Journal of Urology, Vol. 151, No. 5, 01.01.1994, p. 1296-1300.

Research output: Contribution to journalArticle

Stoner, E, Round, E, Ferguson, D, Gormley, GJ, Andriole, GL, Boake, R, Elhilali, M, Perreault, JP, Trachtenburg, J, Norman, R, Rittmaster, R, Braken, BR, Resnick, MI, Brannan, W, Fuselier, H, Bruskewitz, RC, Malek, GH, Cox, CE & Patterson, A 1994, 'Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride', Journal of Urology, vol. 151, no. 5, pp. 1296-1300. https://doi.org/10.1016/S0022-5347(17)35235-7
Stoner, E. ; Round, E. ; Ferguson, D. ; Gormley, G. J. ; Andriole, G. L. ; Boake, R. ; Elhilali, M. ; Perreault, J. P. ; Trachtenburg, J. ; Norman, R. ; Rittmaster, R. ; Braken, B. R. ; Resnick, M. I. ; Brannan, W. ; Fuselier, H. ; Bruskewitz, R. C. ; Malek, G. H. ; Cox, C. E. ; Patterson, Anthony. / Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride. In: Journal of Urology. 1994 ; Vol. 151, No. 5. pp. 1296-1300.
@article{f044c8e4c26c4cb988c9183578bd07aa,
title = "Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride",
abstract = "The clinical experience relating to the detection of prostate cancer in patients participating in 2 large multicenter clinical trials of finasteride in the treatment of benign prostatic hyperplasia is reviewed. A total of 1,645 patients 40 to 83 years old with benign prostatic hyperplasia was randomized to receive 1 or 5 mg. finasteride or placebo once a day for 12 months in a double-blind fashion followed by an open extension study in which all patients were treated with 5 mg. finasteride daily. At entry, all patients were to have a maximum urinary flow rate of 15 ml. per second or less with a voided volume of 150 ml. or more, an enlarged prostate and symptoms of urinary obstruction. Patients with a prostate specific antigen level of 40 ng./ml. or more, or any finding suggestive of prostate cancer were excluded. During the study period 32 cases of prostate cancer were diagnosed: 12 were detected during the 12 months of the controlled study and were evenly distributed among the treatment groups (4 on placebo, and 3 on 1 mg. and 5 on 5 mg. finasteride) and 20 cases were detected in the extension study. From these results we conclude that finasteride-treated patients should be evaluated periodically by digital rectal examination, careful monitoring of prostate specific antigen levels and appropriate investigation of any suspicious findings.",
author = "E. Stoner and E. Round and D. Ferguson and Gormley, {G. J.} and Andriole, {G. L.} and R. Boake and M. Elhilali and Perreault, {J. P.} and J. Trachtenburg and R. Norman and R. Rittmaster and Braken, {B. R.} and Resnick, {M. I.} and W. Brannan and H. Fuselier and Bruskewitz, {R. C.} and Malek, {G. H.} and Cox, {C. E.} and Anthony Patterson",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(17)35235-7",
language = "English (US)",
volume = "151",
pages = "1296--1300",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride

AU - Stoner, E.

AU - Round, E.

AU - Ferguson, D.

AU - Gormley, G. J.

AU - Andriole, G. L.

AU - Boake, R.

AU - Elhilali, M.

AU - Perreault, J. P.

AU - Trachtenburg, J.

AU - Norman, R.

AU - Rittmaster, R.

AU - Braken, B. R.

AU - Resnick, M. I.

AU - Brannan, W.

AU - Fuselier, H.

AU - Bruskewitz, R. C.

AU - Malek, G. H.

AU - Cox, C. E.

AU - Patterson, Anthony

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The clinical experience relating to the detection of prostate cancer in patients participating in 2 large multicenter clinical trials of finasteride in the treatment of benign prostatic hyperplasia is reviewed. A total of 1,645 patients 40 to 83 years old with benign prostatic hyperplasia was randomized to receive 1 or 5 mg. finasteride or placebo once a day for 12 months in a double-blind fashion followed by an open extension study in which all patients were treated with 5 mg. finasteride daily. At entry, all patients were to have a maximum urinary flow rate of 15 ml. per second or less with a voided volume of 150 ml. or more, an enlarged prostate and symptoms of urinary obstruction. Patients with a prostate specific antigen level of 40 ng./ml. or more, or any finding suggestive of prostate cancer were excluded. During the study period 32 cases of prostate cancer were diagnosed: 12 were detected during the 12 months of the controlled study and were evenly distributed among the treatment groups (4 on placebo, and 3 on 1 mg. and 5 on 5 mg. finasteride) and 20 cases were detected in the extension study. From these results we conclude that finasteride-treated patients should be evaluated periodically by digital rectal examination, careful monitoring of prostate specific antigen levels and appropriate investigation of any suspicious findings.

AB - The clinical experience relating to the detection of prostate cancer in patients participating in 2 large multicenter clinical trials of finasteride in the treatment of benign prostatic hyperplasia is reviewed. A total of 1,645 patients 40 to 83 years old with benign prostatic hyperplasia was randomized to receive 1 or 5 mg. finasteride or placebo once a day for 12 months in a double-blind fashion followed by an open extension study in which all patients were treated with 5 mg. finasteride daily. At entry, all patients were to have a maximum urinary flow rate of 15 ml. per second or less with a voided volume of 150 ml. or more, an enlarged prostate and symptoms of urinary obstruction. Patients with a prostate specific antigen level of 40 ng./ml. or more, or any finding suggestive of prostate cancer were excluded. During the study period 32 cases of prostate cancer were diagnosed: 12 were detected during the 12 months of the controlled study and were evenly distributed among the treatment groups (4 on placebo, and 3 on 1 mg. and 5 on 5 mg. finasteride) and 20 cases were detected in the extension study. From these results we conclude that finasteride-treated patients should be evaluated periodically by digital rectal examination, careful monitoring of prostate specific antigen levels and appropriate investigation of any suspicious findings.

UR - http://www.scopus.com/inward/record.url?scp=0028273242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028273242&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(17)35235-7

DO - 10.1016/S0022-5347(17)35235-7

M3 - Article

VL - 151

SP - 1296

EP - 1300

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -